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Received September 12, 2013; accepted November 20, 2013AbstractThe “gold standard” treatment for endometrial cancer is completely staged surgery, followed by radiation or chemotherapy, based on the
final pathological surgical stage and requirements. In the primary treatment of endometrial cancers, hormones are rarely taken into
consideration after primary surgery. Primary treatment with hormones to preserve fertility in younger women with endometrial cancer is an
attractive option, and many successful cases have been reported, although the majority of them finally received definite therapy, including
total hysterectomy. The role of hormone therapy is often delayed in recurrent disease; response rates to progestins and tamoxifen or
aromatase inhibitors in advanced/recurrent endometrial cancers are approximately 15e20% and nearly 10%, respectively. This review is
focused on updated information and recent knowledge on the use of hormones in the management of women with advanced or recurrent
endometrial cancers.
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Uterine corpus cancer is the second most common cancer in
the United States,1 and its incidence has significantly
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1726-4901/Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Assincludes endometrial cancer and uterine sarcoma, based on the
distinguishing characteristics of the uterus. On the basis of
biological and histopathologic variables, endometrial cancer
can be further broken down into two major types, namely,
Type I and Type II. Type I is strongly associated with unop-
posed estrogen, whereas Type II is relatively unrelated to the
overproduction of estrogen.3 In this review, we focus on the
role of hormone therapy in the management of patients with
advanced or recurrent endometrial cancers.
First, a brief introduction to endometrial cancer is required,
for the purpose of identifying the potential population that
may be benefited by hormone therapy.ociation. All rights reserved.
Table 2
Differences between the FIGO 1988 and FIGO 2009 staging systems of
endometrial cancer.
Stage FIGO 1988 FIGO 2009
I Confined to uterine corpus (invasion)
IA (1988, 2009) Limited to endometrium <1/2 myometrium
IB (1988, 2009) <1/2 myometrium 1/2 myometrium
IC (1988) 1/2 myometrium d
II (2009) Confined to cervix Cervical stromal invasion, not
extending beyond the uterus
IIA (1988) Endocervical gland d
IIB (1988) Cervical stroma d
III (1988, 2009) Local and/or regional spread (invasion) of the tumor
IIIA (1988, 2009) Serosa or adnexa or
malignant cytology
Serosa and/or adnexa
IIIB (1988, 2009) Vagina Vagina and/or parametrium
IIIC (1988) Pelvic and/or para-aortic LN
IIIC1 (2009) d Pelvic LN
IIIC2 (2009) d Para-aortic LN
IV (1988, 2009) Bladder and/or bowel mucosa, and/or distant metastases
IVA (1988, 2009) Bladder and bowel mucosa
IVB (1988, 2009) Distant metastases, including intra-abdominal metastases
and/or inguinal LN
Positive cytology has to be reported separately without changing the stage.
Grading (G1, G2, G3) has to be reported separately without changing the
stage.
FIGO ¼ Federation Internationale de Gynecologie et d’Obstetrique;
LN ¼ lymph nodes.
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Detailed information on endometrial cancer has been
extensively reviewed in the past.3 In brief, two types of
endometrial cancer can be clearly defined, based on the
distinct biological and histopathological findings (Table 1).
Type I endometrial cancer includes the following character-
istics: estrogen-related tumor, favorable outcome, well-known
cancer transformation, and positive immunohistochemical
staining for the phosphatase and tensin homolog gene and
hormone receptors.3 By contrast, Type II endometrial cancer
comprises different characteristics, including an older popu-
lation, little association with estrogen, unusual histological
subtypes with p53 mutations, and a strong tendency to inva-
sion and metastasis despite minimal or no invasion within the
uterine cavity, leading to advanced stage, high recurrence
rates, and a poor prognosis.
Endometrial cancers are staged surgically in accordance
with the 2009 French Federation Internationale de Gyneco-
logie et d’Obstetrique (FIGO) staging system (Table 2), which
is a revision of the 1988 FIGO staging system.4 Four major
differences between the 1988 and 2009 FIGO staging systems
for endometrial cancers are: (1) the 1988 FIGO IA and IB are
combined into the 2009 FIGO IA, and the 1988 FIGO IC is
now the 2009 FIGO IB; (2) Stage II no longer has subsets A
and B, and endocervical glandular invasion is considered as
Stage I; (3) positive cytology is no longer part of Stage III; and
(4) pelvic and para-aortic lymph node invasion is classified as
IIIC, based on the poor prognosis.5
The standard surgical staging treatment for endometrial
cancer includes cytology, total hysterectomy, and bilateral
salpingo-oophorectomy with/without the requirement ofTable 1
The basic differences between Type I and Type II endometrial cancers.
Type I Type II
Incidence 80% 20%
Age Varied Postmenopause
Histology Endometrioid Serous, clear
Grade Low High
Clinical behavior Less aggressive More aggressive
Estrogen relation Much evidence Less evidence
BMI High Low

























AR ¼ androgen receptor; BMI ¼ body mass index; EIC ¼ endometrial
intraepithelial carcinoma; EIN ¼ endometrial intraepithelial neoplasia;
ER ¼ estrogen receptor; IHC ¼ immunohistochemical staining;
MSI ¼ microsatellite instability; PR ¼ progesterone receptor;
PTEN ¼ phosphatase and tensin homolog.lymph node sampling and lymph node dissection, although
some modifications are made for different populations based
on differences in intent and conditions, such as fertility pres-
ervation and/or very earlier stage and well-differentiated
endometrioid cancer.3 In theory, oophorectomy might be
beneficial in the management of endometrial cancer,6 because
oophorectomy can remove occult ovarian metastases and
decrease estrogen production.6
In general, the majority of patients have FIGO Stage I
endometrial cancer (72.6% at Taipei Veterans General Hos-
pital) with a favorable 5-year outcome (98.7% and 90.5% for
2009 FIGO IA and IB, respectively).4 However, the prognosis
in advanced/recurrent disease is poor and presents a thera-
peutic challenge, even for those patients with Type I endo-
metrial cancers. Many endometrial cancers express estrogen
(ER) and/or progesterone (PR) receptors; consequently, there
are numerous case reports, retrospective studies, and small
Phase 2 studies that use a variety of hormonal therapies in
patients with recurrent/metastatic endometrial cancers. The
most commonly used agents are progestogens, tamoxifen,
gonadotropin-releasing hormone agonist (GnRH agonist), and
aromatase inhibitors (AIs). The following section highlights
current knowledge on the use of hormonal therapy in recurrent
endometrial cancer.
3. Diagnosis of recurrent endometrial cancer
Before addressing the topic on the use of hormones in the
management of recurrent endometrial cancer, clarifying the
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paramount importance. The endometrial cancer recurrence
rate ranges from 7.7% to 19%.7 The majority of recurrences,
ranging from 68% to 100%, were detected within 3 years,
and the rate of symptomatic recurrence ranged from 70% to
77%.8 Tests used routinely as part of follow-up programs are
physical examination, vaginal vault cytology, chest X-ray,
abdominal pelvic ultrasound, abdominal pelvic computed
tomography, and CA 125. However, recurrences detected
during these incidental tests ranged from 0% to 33%, sug-
gesting that their use seems to be of low value and they
should not be used without new evidence that can aid in
making a decision on the most appropriate follow up for
patients.9 The diagnosis of endometrial cancer is often at an
early stage, and primary treatment, often mediated through
complete staging surgery, usually cures the majority of pa-
tients. In addition, postoperative adjuvant therapy, including
radiation either in the form of vaginal vault brachytherapy,
pelvic external beam radiation, or other modalities, may be
arranged for patients at a higher risk for recurrence, such as
Stage IA, Grade 3, Stage IC, or advanced stage.7 This then
raises questions, including: (1) what is an appropriate strat-
egy for the follow up of these patients who are clinically
disease-free? and (2) do differences in follow-up intervals,
diagnostic interventions, clinical setting, or specialty influ-
ence patient outcomes related to local or distant recurrence,
survival, or quality of life?7 The anatomic locations of re-
currences are roughly equivalent between the local pelvis
and distant sites such as intra-abdominal regions and the
lungs,9 although data from one study showed two-fifths of
patients with local recurrence and the three-fifths with
distant metastases.8 There is some controversy surrounding
the salvage rate among recurrent patients, which ranged from
10% to 38%.10,11 Treatment of recurrent disease depends on
the original stage, location of the recurrence, and previous
treatment.12 The majority of isolated vaginal recurrences in
women with surgical Stage I endometrial cancer can be
successfully salvaged with radiation therapy, with a 5-year
overall survival rate of nearly 75%.12 The prognosis of pa-
tients with distant recurrence is generally not favorable, and
these patients are often treated systemically, including
chemotherapy and hormone therapy. Among these treat-
ments, hormone therapy with progestins has been a favored
option because of its minimal toxicity.12
4. Progesterones/progestins
Progesterone was discovered in 1933. Its effects are
mediated through interaction with the PR, a transcription
factor, and member of a large family of structurally related
gene products known as the nuclear receptor superfamily.13
Two isoforms of the PR, PRA and PRB, are generated by
alternative transcription and translation from the same gene,
because the amino acid sequences are identical and PRB has a
longer N terminus (additional 164 amino acids). Both PRA
and PRB are expressed in the normal endometrium and have
distinct roles.14 For example, alternation of PR isoformexpression or loss of total PR leads to hyperplasia or even
tumor formation.13
It is well known that estrogen-based hormonal therapy in-
creases the incidence of endometrial hyperplasia and cancer,
but the addition of a synthetic progestin (estrogeneprogestin
therapy) prevents the development of endometrial cancer and
might decrease the incidence of the risk of endometrial cancer,
suggesting that progesterone is an important inducer of
endometrial differentiation and an inhibitor of carcinogenesis
mediated through estrogen.15,16
In the early 1950s, endometrial cancers were treated with
progestational agents, and the objective response rate was
approximately 30%.17 The advantages of hormones are that
they are less toxic, less expensive, and easier to administer
than parenteral chemotherapeutic agents, although chemo-
therapy is the standard antineoplastic treatment option for
most women with advanced or recurrent endometrial cancers,
based on the results of the Gynecologic Oncology Group
(GOG) clinical trial 163.18 The GOG 163 showed 34% and
57% objective response rates for these advanced or recurrent
endometrial cancers when doxorubicin plus cisplatin without
or with paclitaxel was used, respectively. The Cochrane
analysis of 1519 patients found that treatment consisting of
more chemotherapy was associated with longer overall sur-
vival and longer progression-free survival, even though serious
acute toxicities were more common in women randomized to
the more intense chemotherapy regimen.19
Frequently used regimens are medroxyprogesterone ace-
tate (MPA; Depo-Provera), ranging from 200 to 500 mg/day,
and megestrol acetate (MA; Megace), ranging from 40 to
320 mg/day. However, for those patients with recurrent
endometrial cancer undergoing progestin therapy, high doses
of MPA or MA seemed not to be superior to low doses of
MPA or MA, because the efficacy did not increase, but the
adverse effects, including edema, weight gain, and the risk of
venous thromboembolism increased significantly (GOG
081).20 In addition, the efficacy of progestin in the man-
agement of recurrent endometrial cancers was less effective
(11e25%; GOG 081 and GOG 121),21e24 compared with the
original reports (30e56%).18,25 Furthermore, the response in
cases of recurrent endometrial cancer treated with progestins
is often partial and the duration is often short (a median 3.2-
month progression-free survival and a median 11.1-month
overall survival in GOG 081),21 although one report
showed that some patients have a progression-free survival
of more than 12 months.26 The response rate of these
recurrent endometrial cancers undergoing progestin treat-
ment can be predicted by the presence of PR in tumors,
because the response rate was 37% in patients with PR-
positive tumors and 8% in patients with PR-negative
tumors.21
5. Some modifications of progestins
With respect to hormone receptor status in GOG 081,21 the
hypothesis27,28 that tamoxifen would prevent PR down-
regulation, and therefore improve response, especially the
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progression-free and overall survival, was tested. An Eastern
Cooperative Oncology Group Study (E4882) randomized pa-
tients to either the standard progestin therapy of MA (20%
response rate: 1 complete and 3 partial among 20 patients) or
the combination of MA and tamoxifen therapy (19% response
rate: 1 complete and 7 partial among 42 patients) and
concluded that the combination of MA and tamoxifen offers
no clinical advantages over MA alone in the treatment of
advanced endometrial cancer.28 However, a Phase II study of
MPA plus tamoxifen (GOG 119) showed a 33% response rate
(6 complete and 13 partial among 58 patients) with a median
3-month progression-free survival and a median 13-month
overall survival; therefore, the authors concluded that the
combination of daily tamoxifen and intermittent weekly MPA
is an active treatment for advanced or recurrent endometrial
cancer.29 Another Phase II study of an alternative course of
MA and tamoxifen (GOG 153) showed a 27% response rate
(12 complete and 3 partial among 56 patients), and up to 53%
of the responders had a response duration of more than 20
months; therefore, the authors concluded that this regimen of
alternating MA and tamoxifen is active in treating endometrial
cancer and may result in a prolonged complete response in
some patients.30 Singh and colleagues further studied the
relationship of ER and PR to clinical GOG 119 outcomes and
concluded that ER-alpha measured in metastatic endometrial
carcinoma tissue before hormonal therapy was statistically
significantly related to clinical response to daily tamoxifen and
intermittent MPA.31 The aforementioned clinical trials are
summarized in Table 3.20e23,26,28e31,38,39
However, a recent Cochrane review questioned the value of
adjuvant progestagens for endometrial cancer, because a meta-
analysis of 4556 patients failed to support its use in the pri-
mary treatment of endometrial cancer.32 This suggested that
further research and development of hormonal manipulation in
endometrial cancer, such as epigenetic modulation, including
methylation, histone acetylation, and others, is warranted.Table 3
Trials of progestin or tamoxifen or combination in metastatic or recurrent endome
Authors (y) Regimen
Thigpen et al20 (1999) MPA 200 mg/day
MPA 1000 mg/day
Lentz et al21 (1996) MA 800 mg/day
Piver et al22 (1980) Depo-Provera
Podratz et al23 (1985) Delalutin, Colprone, or MA
Carlson et al26 (1984) TAM
Pandya et al28 (2001) MA þ tamoxifen
Whitney et al29 (2004) TAM 40 mg/day plus alternating MPA 200 mg/week
Fiorica et al30 (2004) MA 80 mg b.i.d.  3 weeks alternating with TAM 2
Singh et al31 (2007) TAM 40 mg/day plus alternating MPA 200 mg/week
Thigpen et al38 (2001) TAM 20 mg b.i.d.
Rendina et al39 (1984) TAM 20 mg b.i.d.
MPA 1 g/wk intramuscularly
12* ¼ 40% of patients survived more than 1 year; b.i.d. ¼ two times daily; co
hydroxyprogesterone caproate; MA ¼ megestrol acetate; mo ¼ months; MPA ¼
able; OS ¼ overall survival; PFS ¼ progression-free survival; RR ¼ response rate6. Other hormones
The expression of ER in endometrial cancer provides a
rationale for the use of tamoxifen or other selective ER
modulators (SERMs).33 SERMs are often used in the man-
agement of breast cancer in premenopausal women and oste-
oporosis in postmenopausal women, with selection, activation,
and suppression of ER.16,34e37 Tamoxifen has diverse effects
in the pathogenesis of endometrial cancer because of its po-
tential therapeutic effects on an established endometrial cancer
and the potential risk of inducing the formation of endometrial
cancer.35 Thigpen and colleagues used tamoxifen 20 mg two
times/day in the management of advanced or recurrent endo-
metrial cancer, with an overall response rate of 10%, a 1.9-
month median progression-free survival, and an 8.8-month
medial overall survival.38 Rendina and colleagues compared
the effects of tamoxifen and MPA and showed 53.4% and
56.2% response rates, respectively, for the two.39 Rendina et al
also showed promising results with combined tamoxifen and
MPA therapy, with 14 (60.8%) participants in the tamoxifen
group and 15 (62.5%) in the MPA group responding to the
combination therapy when they suffered a relapse of endo-
metrial cancer, experiencing a 2.7-month median progression-
free survival and 14-month overall survial.39 Arzoxifene, a
modification of raloxifene, has been studied in a small Phase II
study that showed a 31% response rate in hormone-receptor-
positive or well-differentiated endometrial cancer, with a
median response of 13.9 months.40
GnRH agonist has been used in the management of various
kinds of benign or malignant gynecological tumors.41e43 It is
mediated either through the direct effect of the GnRHeGnRH
receptor pathway or through downregulation of the GnRH
receptor, producing a subsequent suppression of ovarian
function and decrease of estrogen levels. Studies in the UK
evaluated the efficacy of GnRH agonists in the management of
recurrent endometrial cancer.44,45 An open Phase II observa-
tional trial showed a 35% response rate (6/17), with a mediantrial cancer.
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58 33 d d









lprone ¼ 6,17 alpha-dimethyl-6-dehydroprogesterone; delalutin ¼ 17 alpha-
medroxyprogesterone acetate; n ¼ number of patients; NA ¼ no data avail-
; TAM ¼ tamoxifen; wk ¼ week; y ¼ year of publication.
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same group reported that the response rate was 28% in 32
patients with recurrent endometrial cancer.45 The significantly
greater response rates were in previously irradiated sites,
compared with nonirradiated sites of recurrence, suggesting
that GnRH agonists have a significant and durable antitumor
effect in recurrent endometrial cancer.45 A GOG trial evalu-
ated the effect of GnRH agonist in patients with advanced and
recurrent endometrial cancer, and found an 11% response rate
(2 complete, 3 partial among 42 patients), with a 1.9-month
median progression-free survival and 7.3-month median
overall survival.46
AIs block the aromatase enzyme, resulting in reduced es-
trogen levels and deprive the tumor of growth stimulation.47 A
GOG Phase II trial evaluated the effect of AIs in patients with
advanced or recurrent endometrial cancer and found a 9%
response rate (2 partial, 2 stable among 23 patients).47 Although
the toxicity profile was mild, anastrozole, an AI, had only
minimal activity in an unselected population of patients with
recurrent endometrial cancer.47 A multicenter Phase II trial
conducted by the National Cancer Institute of Canada Clinical
Trials Group further showed the low response rate (9.4%, 1
complete, 2 partial among 28 patients) of letrozole (another AI)
in the management of patients with advanced or recurrent
endometrial cancer.47 However, 11 patients (39%) had stable
disease for a median duration of 6.7 months, suggesting that
letrozole iswell tolerated but has little overall activity in patients
with advanced or recurrent endometrial cancer.48 Table 440,44e48
shows the summary of these trials.
In conclusion, primary advanced or recurrent endometrial
cancer remains an entity with a dismal outcome and with less
than optimal therapeutic options. Patients with metastatic dis-
ease are not curable and should be considered for palliative
chemotherapy. Some data support the use of carboplatin and
paclitaxel as an acceptable alternative to cisplatin-based regi-
mens; however, the options are limited when those patients
progress after first-line treatment.49 In these situations, hormone
therapy, especially progestins with/without tamoxifen, although
response rate is not satisfactory, remains a valid option for some
patients with favorable histologic andmolecular characteristics,
because a cure is impossible and toxicity is a major concern.Table 4
Trials of other hormone regimens in metastatic or recurrent endometrial
cancer, excluding tamoxifen, megestrol acetate (Megace), or
medroxyprogesterone.






McMeekin et al40 (2003) Arzoxifene 20 mg 34 31 13.9 NA
Gallagher et al44 (1991) GnRH agonist 17 35 NA 20
Jeyarajah et al45 (1996) GnRH agonist 32 28 NA 34
Asbury et al46 (2002) GnRH agonist 40 11 1.9 7.3
Rose et al47 (2000) Anastrozole 23 9 1.0 6.0
Ma et al48 (2004) Letrozole 2 mg 28 9.4 6.7 NA
GnRH agonist ¼ gonadotropin-releasing hormone agonist; mo ¼ months;
n ¼ number of patients; OS ¼ overall survival; PFS ¼ progression-free sur-
vival; RR ¼ response rate; y ¼ year of publication.With much more advanced molecular development, new ave-
nues of treatment may enhance the effectiveness of hormone
therapy for endometrial cancer.
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